BrainsWay Receives FDA Clearance for Adolescent Depression Treatment

MT Newswires Live11-13

BrainsWay (BWAY) said Thursday it received US Food and Drug Administration clearance to offer its deep transcranial magnetic stimulation as an add-on treatment for major depressive disorder in patients aged 15 to 21.

The therapy uses magnetic pulses to stimulate brain areas tied to mood and is intended to be used alongside existing care, the company said.

The FDA decision was backed by real-world data from 1,120 adolescents that showed about two-thirds met response after 36 sessions and average symptoms fell by roughly 12 points on a standard depression scale, BrainsWay said.

Safety outcomes were consistent with adult use, and clinicians can now use the same system for adults who failed antidepressants and for adolescents as an adjunct, the company added.

Shares of the company were up over 2.2% in recent Thursday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583647495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583647495","market":"sh","top_or_hot":-1,"title":"BrainsWay Receives FDA Clearance for Adolescent Depression Treatment","media":"MT Newswires Live","content":"<html><body><p> BrainsWay (BWAY) said Thursday it received US Food and Drug Administration clearance to offer its deep transcranial magnetic stimulation as an add-on treatment for major depressive disorder in patients aged 15 to 21.</p><p>The therapy uses magnetic pulses to stimulate brain areas tied to mood and is intended to be used alongside existing care, the company said.</p><p>The FDA decision was backed by real-world data from 1,120 adolescents that showed about two-thirds met response after 36 sessions and average symptoms fell by roughly 12 points on a standard depression scale, BrainsWay said.</p><p>Safety outcomes were consistent with adult use, and clinicians can now use the same system for adults who failed antidepressants and for adolescents as an adjunct, the company added.</p><p>Shares of the company were up over 2.2% in recent Thursday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BrainsWay Receives FDA Clearance for Adolescent Depression Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrainsWay Receives FDA Clearance for Adolescent Depression Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-13 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BrainsWay (BWAY) said Thursday it received US Food and Drug Administration clearance to offer its deep transcranial magnetic stimulation as an add-on treatment for major depressive disorder in patients aged 15 to 21.</p><p>The therapy uses magnetic pulses to stimulate brain areas tied to mood and is intended to be used alongside existing care, the company said.</p><p>The FDA decision was backed by real-world data from 1,120 adolescents that showed about two-thirds met response after 36 sessions and average symptoms fell by roughly 12 points on a standard depression scale, BrainsWay said.</p><p>Safety outcomes were consistent with adult use, and clinicians can now use the same system for adults who failed antidepressants and for adolescents as an adjunct, the company added.</p><p>Shares of the company were up over 2.2% in recent Thursday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BWAY","symbol_name":"Brainsway Ltd.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2583647495","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583647495","pubTimestamp":1763035294,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BrainsWay  said Thursday it received US Food and Drug Administration clearance to offer its deep transcranial magnetic stimulation as an add-on treatment for major depressive disorder in patients aged 15 to 21.The therapy uses magnetic pulses to stimulate brain areas tied to mood and is intended to be used alongside existing care, the company said.The FDA decision was backed by real-world data from 1,120 adolescents that showed about two-thirds met response after 36 sessions and average symptoms fell by roughly 12 points on a standard depression scale, BrainsWay said.Safety outcomes were consistent with adult use, and clinicians can now use the same system for adults who failed antidepressants and for adolescents as an adjunct, the company added.Shares of the company were up over 2.2% in recent Thursday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BWAY":"Brainsway Ltd.","BK4082":"医疗保健设备"},"translate_title":"BrainsWay获得FDA批准用于青少年抑郁症治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BWAY":1},"content_text":"BrainsWay (BWAY) said Thursday it received US Food and Drug Administration clearance to offer its deep transcranial magnetic stimulation as an add-on treatment for major depressive disorder in patients aged 15 to 21.The therapy uses magnetic pulses to stimulate brain areas tied to mood and is intended to be used alongside existing care, the company said.The FDA decision was backed by real-world data from 1,120 adolescents that showed about two-thirds met response after 36 sessions and average symptoms fell by roughly 12 points on a standard depression scale, BrainsWay said.Safety outcomes were consistent with adult use, and clinicians can now use the same system for adults who failed antidepressants and for adolescents as an adjunct, the company added.Shares of the company were up over 2.2% in recent Thursday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583647495","isCrawlerRequest":true}